Society of Gynecologic Oncology Annual Meeting on Women’s Cancer

Meghan K. Berkenstock, MD, discusses the growing need for strong collaboration between ophthalmologists and gynecologic oncology care teams.

Pembrolizumab inspired a 70% risk reduction in women with mismatch repair–deficient advanced endometrial cancer and a 46% risk reduction in patients with mismatch repair–proficient disease.

With a follow-up of 11.7 months, the estimated 12-month progression-free survival rate was 81% in patients who received neoadjuvant olaparib for BRCA-positive ovarian cancer.

Mary Katherine Montes de Oca, MD, discusses the potential benefit of cryocompression therapy in preventing peripheral neuropathy in patients with gynecologic cancers who are receiving chemotherapy.

Patients with ovarian cancer who received hyperthermic intraperitoneal chemotherapy with cytoreductive surgery did not experience worse health-related quality of life, according to investigators.

Dostarlimab met its primary end point in the phase 3 RUBY trial by increasing the 2-year progression-free survival rate to 36.1%, compared with 18.1% with placebo.

In the all-comer population, the overall response rate was 33.8%, including a complete response rate of 7.5% and a partial response rate of 26.3%.

Research presented at the 2023 Society of Gynecologic Oncology Annual Meeting On Women’s Health suggests that the Carolina frailty index score may be useful for women with ovarian cancer.

The gynecological cancer lymphedema questionnaire and the lower extremity lymphedema screening questionnaire showed a demonstrable correlation in total scores, according to an analysis of women with advanced endometrial cancer.